Global Endoscopic Hemostasis Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

Endoscopic Hemostasis Market Size

• The global endoscopic hemostasis market size was valued at USD 2.57 billion in 2024 and is expected to reach USD 4.93 billion by 2032, at a CAGR of 8.50% during the forecast period
• The market growth is largely fueled by the increasing adoption of advanced endoscopic technologies and minimally invasive procedures, which improve patient outcomes and reduce recovery times in gastrointestinal, surgical, and other clinical settings
• Furthermore, rising demand for efficient, precise, and safe hemostasis solutions is driving the adoption of Endoscopic Hemostasis devices. These converging factors are accelerating the uptake of Endoscopic Hemostasis solutions, thereby significantly boosting the industry's growth

Endoscopic Hemostasis Market Analysis

• The endoscopic hemostasis market is witnessing significant growth, driven by the rising prevalence of gastrointestinal bleeding, increasing adoption of minimally invasive procedures, and advancements in endoscopic technologies
• These factors are enhancing procedural efficiency, improving patient outcomes, and reducing hospitalization duration
• North America dominated the endoscopic hemostasis market with the largest revenue share of 41.28% in 2024, supported by advanced healthcare infrastructure, high adoption of innovative endoscopic devices, and substantial investments in hospital and clinical facilities. The U.S. experienced notable growth due to increasing prevalence of GI disorders, rising awareness among physicians regarding endoscopic hemostasis techniques, and innovations in high-precision endoscopic tools
• Asia-Pacific is expected to be the fastest-growing region in the endoscopic hemostasis market during the forecast period, attributed to increasing healthcare infrastructure investments, growing awareness of minimally invasive procedures, rising prevalence of gastrointestinal diseases, and expanding medical tourism in countries such as China, India, and Japan
• The upper gastrointestinal bleeding (UGIB) diseases segment dominated the endoscopic hemostasis market with the largest market revenue share of 47.5% in 2024, attributed to the higher incidence of peptic ulcers, varices, and erosive gastritis. Endoscopic hemostasis for UGIB is widely recognized for its clinical efficacy, rapid bleeding control, and ability to reduce hospital stay and complications

Report Scope and Endoscopic Hemostasis Market Segmentation    

Endoscopic Hemostasis Market Trends

Enhanced Convenience Through Technological Advancements

• A significant and accelerating trend in the global endoscopic hemostasis market is the deepening integration of advanced imaging, precision delivery, and minimally invasive technologies. This fusion of innovations is significantly enhancing procedural accuracy, patient safety, and operational efficiency in gastrointestinal, cardiovascular, and other endoscopic interventions
  • For instance, modern endoscopic hemostasis systems integrate high-definition imaging and precision thermal, mechanical, or topical agents to achieve rapid and controlled bleeding management. Devices such as multipurpose hemostatic clips, thermal coagulation probes, and topical hemostatic sprays allow clinicians to manage complex bleeding situations with minimal tissue trauma
• Advanced digital monitoring and real-time visualization enable clinicians to evaluate hemostatic effectiveness instantly, improving procedural outcomes and reducing the need for repeat interventions. Some systems also provide automated feedback or pressure control mechanisms for optimal application of hemostatic agents
• The integration of ergonomically designed endoscopic tools with enhanced imaging systems allows surgeons and gastroenterologists to perform complex procedures with improved comfort and reduced fatigue. This contributes to greater procedural accuracy and shorter operation times
• These trends towards more intelligent, precise, and minimally invasive hemostatic solutions are fundamentally reshaping clinical expectations for patient outcomes. Companies such as Boston Scientific, Cook Medical, and Medtronic are advancing endoscopic hemostasis devices with features such as dual-action clips, improved delivery mechanisms, and enhanced endoscope compatibility
• The demand for endoscopic hemostasis solutions is growing rapidly across hospitals, ambulatory surgical centers, and specialty clinics, as clinicians increasingly prioritize safety, efficiency, and comprehensive therapeutic capabilities

Endoscopic Hemostasis Market Dynamics

Driver

Rising Incidence of Gastrointestinal and Surgical Bleeding Disorders

• The increasing prevalence of gastrointestinal bleeding, post-surgical bleeding, and other hemorrhagic conditions is a significant driver for the growth of the Endoscopic Hemostasis market
  • For instance, in 2024, rising cases of peptic ulcer disease, esophageal varices, and anticoagulant-induced bleeding have driven hospitals to adopt advanced hemostasis devices for rapid and effective management
• Clinicians are seeking minimally invasive, precise, and reliable tools that reduce the risk of complications, shorten procedure times, and minimize patient recovery periods
• Endoscopic hemostasis systems allow real-time visualization and controlled intervention, which are critical in emergency bleeding scenarios, contributing to increased adoption in hospital and outpatient settings
• Furthermore, the growing adoption of endoscopic procedures over open surgeries, due to lower risk and shorter hospital stays, propels the demand for effective hemostasis solutions
• The integration of multifunctional devices and improved delivery mechanisms enhances procedural versatility, supporting broader clinical adoption across gastrointestinal, cardiovascular, and surgical departments

Restraint/Challenge

High Costs and Technical Complexity

• High initial costs of advanced endoscopic hemostasis systems can limit adoption in smaller clinics or developing regions, where budget constraints are significant
• Complexity in operating multifunctional devices may require extensive clinician training and proficiency, slowing adoption in facilities with limited skilled personnel
• Some devices have limited compatibility with existing endoscopic systems, requiring additional investments in infrastructure and accessories
• Regular maintenance, sterilization, and device calibration add to operational costs and may challenge resource-constrained hospitals
• The lack of standardized protocols for using advanced hemostasis devices can lead to inconsistent clinical outcomes, discouraging adoption in certain facilities
• In some cases, high dependency on operator skill for precise device deployment can result in procedure variability, increasing hesitancy among less experienced clinicians
• Reimbursement and insurance coverage for advanced hemostasis procedures vary significantly across regions, limiting affordability for patients and adoption by healthcare providers
• Supply chain limitations, including availability of specialized consumables or replacement parts, can delay procedures and restrict consistent use in high-volume hospitals
• Potential adverse events, such as tissue damage or incomplete hemostasis, may occur if devices are not used correctly, raising liability concerns for hospitals and practitioners
• Overcoming these challenges through affordable device solutions, simplified designs, training programs, and better reimbursement policies is essential for wider market growth

Endoscopic Hemostasis Market Scope

The Endoscopic Hemostasis market is segmented into four notable segments based on type, indication, end user, and application.

• By Type

On the basis of type, the market is segmented into mechanical devices, injection devices, thermal devices, and topical devices. The mechanical devices segment dominated the largest market revenue share of 41.8% in 2024, driven by their proven efficacy in controlling gastrointestinal bleeding, ease of use during endoscopic procedures, and wide adoption across hospitals and specialty clinics. Mechanical devices such as clips and band ligation tools are highly reliable for hemostasis, require minimal setup time, and can be deployed in various anatomical sites. Their compatibility with standard endoscopes and high success rate in clinical outcomes further bolster demand. Hospitals and ambulatory surgical centers often prefer mechanical devices due to their predictable performance, reduced procedure time, and ability to handle acute bleeding events efficiently. In addition, ongoing innovations and product refinements continue to enhance safety, ease of deployment, and procedural efficiency, reinforcing their dominance in the market.

The injection devices segment is expected to witness the fastest CAGR of 22.3% from 2025 to 2032, fueled by increasing demand in both upper and lower gastrointestinal bleeding indications. Injection devices provide precise delivery of hemostatic agents, are minimally invasive, and often complement other therapeutic modalities. The growing prevalence of gastrointestinal disorders, the rising number of endoscopic procedures, and favorable clinical outcomes contribute to their rapid adoption. Expansion of endoscopic services in emerging regions and increasing procedural volume in ambulatory centers further accelerate growth. Moreover, the development of advanced injection systems with better control and reduced complication rates makes them an attractive choice for clinicians, driving consistent market expansion.

• By Indication

On the basis of indication, the market is segmented into upper gastrointestinal bleeding diseases, lower gastrointestinal bleeding diseases, and others. The upper gastrointestinal bleeding (UGIB) diseases segment accounted for the largest market revenue share of 47.5% in 2024, attributed to the higher incidence of peptic ulcers, varices, and erosive gastritis. Endoscopic hemostasis for UGIB is widely recognized for its clinical efficacy, rapid bleeding control, and ability to reduce hospital stay and complications. Hospitals and specialty clinics prefer UGIB procedures due to standardized treatment protocols, high success rates, and growing patient awareness. Clinical guidelines advocating early endoscopic intervention for UGIB further support market demand. Moreover, the availability of mechanical, thermal, and injection devices optimized for UGIB enhances procedural efficiency and safety, reinforcing the dominance of this indication segment.

The lower gastrointestinal bleeding (LGIB) diseases segment is expected to witness the fastest CAGR of 20.8% from 2025 to 2032, driven by rising prevalence of diverticulosis, colorectal polyps, and vascular malformations. LGIB often requires complex endoscopic techniques and advanced hemostatic devices, creating opportunities for innovative solutions. Increasing screening programs for colorectal disorders, growing awareness about early intervention, and expansion of gastroenterology centers globally contribute to the rapid growth of this segment. Advanced devices providing precise hemostasis in difficult-to-access areas, combined with rising procedural expertise, accelerate adoption in both developed and emerging regions.

• By End User

On the basis of end user, the market is segmented into hospitals, specialty clinics, ambulatory centers, surgical centers, and others. The hospitals segment dominated the largest market revenue share of 50.2% in 2024, owing to their high procedural volume, availability of skilled endoscopists, and comprehensive infrastructure supporting complex hemostasis interventions. Hospitals often invest in a wide range of endoscopic hemostasis devices to manage acute bleeding events effectively, ensure patient safety, and meet clinical guidelines. The increasing focus on reducing hospitalization duration and enhancing procedural success rates further drives the adoption of advanced devices in hospital settings.

The specialty clinics segment is expected to witness the fastest CAGR of 21.5% from 2025 to 2032, propelled by the rising number of outpatient endoscopic procedures and minimally invasive treatments. Specialty clinics provide targeted services for gastrointestinal disorders, offering convenient, cost-effective, and timely procedures for patients. Expansion of such clinics in urban and semi-urban areas, along with the integration of advanced hemostasis devices, enhances patient throughput and clinical outcomes, driving rapid growth in this end-user segment.

Endoscopic Hemostasis Market Regional Analysis

• North America dominated the endoscopic hemostasis market with the largest revenue share of 41.28% in 2024, supported by advanced healthcare infrastructure, high adoption of innovative endoscopic devices, and substantial investments in hospital and clinical facilities
• The region’s growth is further driven by rising prevalence of gastrointestinal disorders, increasing geriatric population, favorable reimbursement policies, and continuous technological advancements in minimally invasive endoscopic therapies
• The market experienced notable growth due to the increasing prevalence of gastrointestinal disorders, rising awareness among physicians regarding endoscopic hemostasis techniques, and innovations in high-precision endoscopic tools

U.S. Endoscopic Hemostasis Market Insight

The U.S. endoscopic hemostasis market captured the largest revenue share within North America in 2024, fueled by rising demand for minimally invasive procedures and adoption of advanced, high-resolution endoscopic devices. Growing prevalence of gastrointestinal bleeding and increasing focus on improving patient outcomes further propels market growth. In addition, hospitals and specialty clinics are increasingly integrating state-of-the-art endoscopic systems to enhance procedural efficiency and reduce hospitalization duration.

Europe Endoscopic Hemostasis Market Insight

The Europe endoscopic hemostasis market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by rising incidence of gastrointestinal diseases, increasing adoption of advanced endoscopic procedures, and well-established healthcare infrastructure. The growth is also supported by government initiatives promoting minimally invasive procedures and a preference for advanced medical technologies across hospitals and clinics.

U.K. Endoscopic Hemostasis Market Insight

The U.K. endoscopic hemostasis market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by increasing prevalence of gastrointestinal disorders and rising awareness among healthcare professionals regarding the benefits of endoscopic hemostasis. Hospitals and outpatient clinics are progressively adopting innovative hemostasis devices, which enhance procedural precision and patient safety.

Germany Endoscopic Hemostasis Market Insight

The Germany endoscopic hemostasis market is expected to expand at a considerable CAGR during the forecast period, fueled by increasing awareness of gastrointestinal disorders, growing adoption of minimally invasive procedures, and demand for technologically advanced and high-precision endoscopic tools. Hospitals and specialty clinics are investing in state-of-the-art devices to improve patient care and procedural efficiency.

Asia-Pacific Endoscopic Hemostasis Market Insight

The Asia-Pacific endoscopic hemostasis market is poised to grow at the fastest CAGR during the forecast period, driven by increasing healthcare infrastructure investments, growing awareness of minimally invasive procedures, rising prevalence of gastrointestinal diseases, and expanding medical tourism in countries such as China, India, and Japan. Adoption is further supported by technological advancements, rising disposable incomes, and increasing government initiatives to modernize healthcare facilities.

Japan Endoscopic Hemostasis Market Insight

The Japan endoscopic hemostasis market is gaining momentum due to rapid urbanization, technological advancements in medical devices, and increasing demand for minimally invasive procedures. Hospitals and specialized clinics are increasingly adopting advanced endoscopic hemostasis systems, enhancing procedural safety and efficiency, while improving patient outcomes.

China Endoscopic Hemostasis Market Insight

The China endoscopic hemostasis market accounted for the largest market revenue share in Asia-Pacific in 2024, attributed to the country’s expanding healthcare infrastructure, rising prevalence of gastrointestinal disorders, and growing investments in advanced medical technologies. Adoption of high-precision endoscopic tools and minimally invasive procedures in hospitals and specialty clinics is accelerating market growth, supported by technological innovation and increasing patient awareness.

Endoscopic Hemostasis Market Share

The Endoscopic Hemostasis industry is primarily led by well-established companies, including:

• Boston Scientific Corporation (U.S.)
• CONMED Corporation (U.S.)
• Cook (U.S.)
• Diversatek, Inc. (U.S.)
• Olympus Corporation (Japan)
• STERIS plc (Ireland)
• Micro-Tech Endoscopy (China)
• Integra LifeSciences Corporation (U.S.)
• Sklar Instruments (U.S.)
• Merit Medical Systems (U.S.)
• Medtronic (Ireland)
• B. Braun SE (Germany)
• Medline Industries, Inc. (U.S.)
• TAEWOONG (South Korea)
• Erbe Elektromedizin GmbH (Germany)

Latest Developments in Global Endoscopic Hemostasis Market

• In February 2021, EndoClot Plus, Inc. received FDA clearance for its EndoClot Polysaccharide Hemostatic System (PHS), designed to control upper and lower gastrointestinal bleeding using starch-derived Absorbable Modified Polymers (AMP). This launch provided gastroenterologists with a non-thermal, non-traumatic solution for hemostasis, strengthening the company’s position in the U.S. GI bleeding management market
• In September 2024, Ovesco Endoscopy AG announced the European availability of its OTSC neo System, an updated version of its over-the-scope clip (OTSC) designed for endoscopic treatment of GI bleeding and closure of wall lesions. The product introduced improved handling, stronger tissue compression, and broader applicability in complex cases, reflecting Ovesco’s innovation in hemostatic clipping systems

SKU-66666